Macrophage Therapeutics, a Subsidiary of Navidea Biopharmaceuticals, Executes Securities Purchase Agreement for $2.5 Million Financing and Receives Initial Funding Mar 13, 2015
Navidea and Norgine Enter European Commercial Partnership for Lymphoseek®; Navidea to Receive $2 Million Upfront Payment Mar 5, 2015
Macrophage Therapeutics, a Subsidiary of Navidea Biopharmaceuticals, Appoints Leading Experts to Therapeutics-Focused Scientific Advisory Board Feb 27, 2015
Navidea Biopharmaceuticals to Announce Fourth Quarter and Year-End 2014 Financial Results on March 5, 2015 Feb 26, 2015
Lymphoseek® Data Presented in European Medical Conference Reinforces Clinical Value in Head & Neck Cancer of the Oral Cavity Feb 18, 2015
Lymphoseek® Results from Phase 3 Clinical Trial in Oral Cavity Cancer of the Head and Neck Published in Annals of Surgical Oncology Feb 17, 2015
Navidea to Report Preliminary 2014 Revenue and Present at BIO CEO & Investor Conference February 9 Feb 2, 2015
